查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1590808

胃癌治療藥物市場：依分子類型、化療系列和給藥途徑- 2025-2030 年全球預測

Gastric Cancer Drugs Market by Molecule Type (Biologics, Small Molecules), Lines of Chemotherapy (First-line Chemotherapy, Second-line Chemotherapy), Route of Administration - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年胃癌治療市場價值為38.3億美元，預計到2024年將達到40.6億美元，複合年成長率為6.14%，到2030年預計將達到58.1億美元。

胃癌治療的範圍包括治療影響胃黏膜組織的胃癌的治療方法的開發、製造和應用。這包括化療、標靶治療和免疫治療藥物。全球胃癌發病率上升推動了對這些藥物的需求不斷增加，需要更有效的治療來提高患者的生存率和生活品質。治療主要針對醫療保健提供者，包括醫院和診所以及探索治療技術進步的研究機構。最終用途範圍也延伸至製藥公司、研究機構和醫療機構，旨在將先進的治療方法融入癌症治療通訊協定中。

主要市場統計
基準年[2023] 38.3億美元
預測年份 [2024] 40.6億美元
預測年份 [2030] 58.1億美元
複合年成長率（%） 6.14%

市場洞察揭示了關鍵的成長要素，例如提高對胃癌症狀的認知、提高藥物療效的生物技術進步以及癌症研究資金的可用性。亞太地區，尤其是中國和日本，由於患病率高且醫療保健支出不斷增加，因此具有巨大潛力。利用機會的建議包括製藥公司和生技新興企業之間的策略聯盟，以及增加對新治療方法研發的投資。

然而，也存在一些限制，例如高昂的研發成本和嚴格的監管核准可能會延遲藥物的上市。此外，他們還面臨諸如抗藥性和患者治療效果差異等挑戰。為了克服這些問題，關注個人化醫療並進行適應性臨床試驗是非常有益的。

需要創新的領域包括開發協同增強治療效果的聯合治療，以及利用人工智慧進行早期診斷和個人化治療計畫。利用基因組學的進步來了解遺傳傾向也可能促進產品差異化。整體而言，市場格局競爭激烈但前景廣闊，只要公司能夠適應競爭格局並投資以患者為中心的解決方案，透過技術創新和策略聯盟就有巨大的成長空間。

市場動態：揭示快速發展的胃癌藥物市場的關鍵市場洞察

供需的動態交互作用正在改變胃癌藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 由於肥胖病例和吸煙人口的增加，胃癌發生率增加
    • 轉移性胃癌新治療方法簡介
    • 提高對胃癌狀和原因的認知
  • 市場限制因素
    • 嚴格的藥品核准法規和政策
  • 市場機會
    • 加速胃癌治療藥物的研發
    • 生物相似藥在腫瘤學領域的快速普及
  • 市場挑戰
    • 假藥的可用性

波特五力：駕馭胃癌藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對胃癌藥物市場的影響

外部宏觀環境因素在塑造胃癌治療市場的表現動態中發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解胃癌治療藥物市場的競爭狀況

胃癌治療藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣胃癌治療市場供應商績效評估

FPNV定位矩陣是評估胃癌治療市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製胃癌治療市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對胃癌藥物市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 隨著肥胖和吸菸者的增加，胃癌發生率增加
      • 轉移性胃癌新治療方法介紹
      • 提高對胃癌狀和原因的認知
    • 抑制因素
      • 嚴格的藥品核准法規和政策
    • 機會
      • 加速胃癌治療藥物的研發
      • 生物相似藥在腫瘤學的快速採用
    • 任務
      • 假藥的可用性
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依分子類型分類的胃癌治療藥物市場

  • 生物製藥
  • 小分子

第7章 胃癌治療藥物市場化療線

  • 第一線化療
  • 第二化療

第8章胃癌治療藥物市場：依給藥途徑

  • 口服
  • 胃腸外的

第9章 北美及南美胃癌藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區胃癌治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲胃癌藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Amgen Inc.
  • ASLAN Pharmaceuticals Pte Ltd
  • AstraZeneca PLC
  • Bayer AG
  • Bristol Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • SELLAS Life Sciences Group, Inc.
  • Taiho Pharmaceutical Co., Ltd.
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-437E9896A4F6

The Gastric Cancer Drugs Market was valued at USD 3.83 billion in 2023, expected to reach USD 4.06 billion in 2024, and is projected to grow at a CAGR of 6.14%, to USD 5.81 billion by 2030.

The scope of gastric cancer drugs encompasses the development, production, and application of therapies designed to treat gastric cancer, which affects the stomach's mucosal tissue. This includes chemotherapy, targeted therapy, and immunotherapy drugs. The increasing necessity for these drugs is driven by the rising incidence of gastric cancer globally, necessitating more effective treatments to improve patient survival rates and life quality. Applications primarily focus on healthcare providers, including hospitals and clinics, along with research institutions exploring advancements in treatment techniques. End-use scope extends to pharmaceutical companies, research bodies, and medical institutions, aiming to integrate advanced treatments into cancer care protocols.

KEY MARKET STATISTICS
Base Year [2023] USD 3.83 billion
Estimated Year [2024] USD 4.06 billion
Forecast Year [2030] USD 5.81 billion
CAGR (%) 6.14%

Market insights reveal key growth factors such as heightened awareness of gastric cancer symptoms, advancements in biotechnology enhancing drug efficacy, and the availability of funding for cancer research. The Asia-Pacific region, particularly China and Japan, presents significant potential due to high prevalence rates and increasing healthcare expenditure. Recommendations to capitalize on opportunities include strategic partnerships between pharmaceutical firms and biotech startups, and increased investment in R&D for novel treatment options.

However, limitations exist in the form of substantial R&D costs and stringent regulatory approvals that can delay drug launches. Additionally, the market faces challenges such as drug resistance and variability in treatment responses among patients. To overcome these, focusing on personalized medicine and implementing adaptive clinical trials could be highly beneficial.

Areas ripe for innovation include the development of combination therapies that synergistically enhance treatment effectiveness, as well as leveraging AI for early diagnosis and personalized treatment plans. Exploiting advancements in genomics to understand genetic predispositions could also foster product differentiation. Overall, the gastric cancer drugs market is competitive yet promising, with significant scope for growth through technological innovations and strategic alliances, provided that businesses can navigate the regulatory landscape and invest in patient-centric solutions.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Gastric Cancer Drugs Market

The Gastric Cancer Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidences of the stomach cancer with the increasing number of obesity cases and smoking population
    • Introduction of novel therapies for metastatic stomach cancer
    • Increase in awareness about the symptoms and causes of gastric cancer
  • Market Restraints
    • Stringent regulations and policies for approval of the drugs
  • Market Opportunities
    • Accelerating research and development activities in the drugs for gastic cancer
    • Rapid adoption of biosimilars in oncology
  • Market Challenges
    • Availability of the counterfeit drugs

Porter's Five Forces: A Strategic Tool for Navigating the Gastric Cancer Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Gastric Cancer Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Gastric Cancer Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Gastric Cancer Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Gastric Cancer Drugs Market

A detailed market share analysis in the Gastric Cancer Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Gastric Cancer Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Gastric Cancer Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Gastric Cancer Drugs Market

A strategic analysis of the Gastric Cancer Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Gastric Cancer Drugs Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., ASLAN Pharmaceuticals Pte Ltd, AstraZeneca PLC, Bayer AG, Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., SELLAS Life Sciences Group, Inc., Taiho Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Gastric Cancer Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Molecule Type, market is studied across Biologics and Small Molecules.
  • Based on Lines of Chemotherapy, market is studied across First-line Chemotherapy and Second-line Chemotherapy.
  • Based on Route of Administration, market is studied across Oral and Parenteral.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of the stomach cancer with the increasing number of obesity cases and smoking population
      • 5.1.1.2. Introduction of novel therapies for metastatic stomach cancer
      • 5.1.1.3. Increase in awareness about the symptoms and causes of gastric cancer
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent regulations and policies for approval of the drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Accelerating research and development activities in the drugs for gastic cancer
      • 5.1.3.2. Rapid adoption of biosimilars in oncology
    • 5.1.4. Challenges
      • 5.1.4.1. Availability of the counterfeit drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Gastric Cancer Drugs Market, by Molecule Type

  • 6.1. Introduction
  • 6.2. Biologics
  • 6.3. Small Molecules

7. Gastric Cancer Drugs Market, by Lines of Chemotherapy

  • 7.1. Introduction
  • 7.2. First-line Chemotherapy
  • 7.3. Second-line Chemotherapy

8. Gastric Cancer Drugs Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Oral
  • 8.3. Parenteral

9. Americas Gastric Cancer Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Gastric Cancer Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Gastric Cancer Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Amgen Inc.
  • 2. ASLAN Pharmaceuticals Pte Ltd
  • 3. AstraZeneca PLC
  • 4. Bayer AG
  • 5. Bristol Myers Squibb Company
  • 6. Eli Lilly and Company
  • 7. F. Hoffmann-La Roche AG
  • 8. GlaxoSmithKline PLC
  • 9. Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • 10. Merck & Co., Inc.
  • 11. Novartis AG
  • 12. Pfizer Inc.
  • 13. SELLAS Life Sciences Group, Inc.
  • 14. Taiho Pharmaceutical Co., Ltd.
  • 15. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GASTRIC CANCER DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. GASTRIC CANCER DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. GASTRIC CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. GASTRIC CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GASTRIC CANCER DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GASTRIC CANCER DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY FIRST-LINE CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY SECOND-LINE CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 23. BRAZIL GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 26. CANADA GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. MEXICO GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 36. ASIA-PACIFIC GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 40. AUSTRALIA GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. CHINA GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. INDIA GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. INDONESIA GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. JAPAN GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. MALAYSIA GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. PHILIPPINES GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. SINGAPORE GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. SOUTH KOREA GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. TAIWAN GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. THAILAND GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. VIETNAM GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 80. DENMARK GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. EGYPT GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. FINLAND GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. FRANCE GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. GERMANY GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. ISRAEL GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. ITALY GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. NETHERLANDS GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 104. NIGERIA GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. NORWAY GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. POLAND GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. QATAR GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. RUSSIA GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. SAUDI ARABIA GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. SOUTH AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. SPAIN GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. SWEDEN GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. SWITZERLAND GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. TURKEY GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. UNITED ARAB EMIRATES GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED KINGDOM GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. GASTRIC CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 144. GASTRIC CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023